Researchers at the University of Liverpool have developed a breakthrough technology that identifies molecular markers in
early lung cancer.
The new technology, created in collaboration with SEQUENOM, developers of genetic analysis products, and Methexis Genomics,
uses a DNA analysis technique called methylation profiling to detect cells in the lung that are likely to become cancerous.
There are a number of genetic mechanisms that can alter the characteristics of a normal cell and change it into a cancer
cell. One of these mechanisms is methylation, which causes a change in the DNA structure of particular genes and results in
altering its control - this may switch the gene on or off at the wrong time in the cell cycle.
Dr Lakis Liloglou, Head of the University's Lung Cancer Molecular Biomarkers Group, explains: "This is of particular
importance in lung cancer research, as the changes in methylation status of the DNA are considered to be a marker for early
disease detection.
"Even though DNA methylation analysis has been a previous area of research, prior techniques had a range of technical
limitations, that prevented them from being of any real clinical use. This newly developed method overcomes many of the
problems and combines the sensitivity of high-powered microscopes with the capability of analysing many samples at a time."
As part of their research to develop the new technology, the team, based at the University of Liverpool Cancer Research
Centre, analysed the methylation profile of 47 genes in lung specimens from 48 patients with a history of smoking. The genes
that were selected were known to be involved in cancer development and in this study they were able to accurately determine
the relationship between gene methylation in normal and tumour tissue, which in the long term will be of enormous value in
identifying high risk individuals.
Professor John Field, Director of the Roy Castle Lung Cancer Research Programme, said: "Early detection of lung cancer is the
prime objective of our research programme. This depends on the identification of early biomarkers in patients who are at risk
of developing the disease prior to clinical symptoms."
"The partnership between the University and Sequenom has provided a breakthrough in our goal to detect early genetic changes
in individuals who are at the highest risk."
The research is being presented this week at the 96th annual meeting of the American Association for Cancer Research (AACR)
in Anaheim, California.
1 The University of Liverpool is one of the UK's leading research institutions with a prodigious spread of expertise - from
the humanities and social sciences to engineering, science, veterinary science and medicine. It attracts collaborative and
contract research commissions from a wide range of national and international organisations - commissions valued at more than
£80 million annually.
2 SEQUENOM is committed to providing the best genetic analysis products that translate genomic science into superior
solutions for biomedical research, molecular medicine and agricultural applications.
3 Methexis Genomics NV is a Ghent, Belgium-based genomics company dedicated to the development of proprietary technologies
for improving the efficiency and reducing the cost of genetic variation analysis in human health and agriculture
applications.
4 Dr Liloglou's post is funded by the Roy Castle Lung Cancer Foundation. The charity is the only one in the world wholly
dedicated to research into the early detection of lung cancer. The Foundation also offers patient support, advocacy and
information network and operates a very successful smoking cessation service.
For further information:
Kate Spark, Media Relations Manager
Tel: 0151 794 2247, Mobile: 07970 247391, E-mail: kate.sparkliv.ac
Joanna Robotham, Press Officer
Tel: 0151 794 2026, Mobile: 07970 247396, E-mail: joanna.robothamliv.ac
Samantha Martin, Assistant Press Officer
Tel: 0151 794 2248, Mobile: 07970 247836, E-mail: samantha.martinliv.ac
liv.ac